While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

When a drug product is unstable—whether it is sensitive to light, shear, or temperature—the formulation and sterile filling ...

Lilly breaking through the $1tn market cap ceiling comes as investors have increasingly turned to pharma stocks. The S&P 500 ...

An FDA officer explains the agency’s compliance requirements for importing pharmaceuticals and biologics and processes.

The industry is showing enthusiasm for novel technologies that improve safety and carry innovation potential including in ...

In 2024, the FDA granted a record 63 designations to antibody drug conjugates (ADCs), nearly double the previous high of 35 ...

AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in Frederick, Maryland, US.

Advances in large-volume injectors are enabling faster, more comfortable, at-home treatment. Patient-centric design, ...

OSR Company Vaximm has linked with investor BCM Europe (BCME) for a potential exclusive worldwide licence for Vaximm’s VXM01.

Results from a survey from an independent, third party research firm, TechValidate, indicate that more than half of 606 ...

Galapagos CEO Henry Gosebruch says the recent uptick in M&A activity is a positive development for the biotech as it pursues ...

“This change is deeply troubling because it is false and lacks transparency. There is no scientific rationale for CDC to ...